ESR1 and breast carcinoma: Tamoxifen treatment of breast cancer patients or as a chemopreventive agent has in fact been associated with increased risk of endometrial cancer[44,45] thought to be due to its estrogenic activity on the endometrium via ER or as a result of tamoxifen-DNA adduct formation[46].